PerkinElmer, Inc. (PKI) and Horizon Discovery Group plc (HZD.L) have reached an agreement on the terms of a recommended all cash offer, under which PerkinElmer will acquire Horizon for approximately $383 million. The deal has a total enterprise value of approximately $368 million. Headquartered in Cambridge, UK, Horizon Discovery Group is a provider of CRISPR and RNAi reagents, cell models, cell engineering and base editing offerings.
PerkinElmer expects the acquisition to be modestly accretive to non-GAAP earnings in year-one following the close.
For comments and feedback contact: editorial@rttnews.com
Business News